MLYS
HealthcareMineralys Therapeutics, Inc.
$23.98-1.04 (-4.16%)
Prev Close
$25.02
Open
$24.53
High
$24.63
Low
$23.60
Volume
1.85M
Market Cap
$1.81B
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Mineralys Therapeutics, Inc. (MLYS) has been mixed between buying and selling, with 3 insider purchases totaling $48.50M and 32 insider sales totaling $77.71M. The most recent insider transaction was by Rodman David Malcom (officer: Chief Medical Officer), who sold $10.7K worth of shares on Mar 17, 2026. Mineralys Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.81B.
Buys (12M)
3
$48.50M
Sells (12M)
32
$77.71M
Net Activity
Net Seller
$29.21M
Active Insiders
9
last 12 mo
MLYS Price Chart
MLYS Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 417 | $25.65 | $10.7K | 76,140 |
| Mar 16, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 20,406 | $26.61 | $543.0K | 82,489 |
| Mar 10, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 2,171 | $26.84 | $58.3K | 82,489 |
| Feb 17, 2026↗ | Rodman David Malcom | Chief Medical Officer | Sell | 417 | $27.59 | $11.5K | 0 |
| Feb 13, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 16,863 | $28.05 | $473.0K | 50,958 |
| Feb 11, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 2,171 | $30.21 | $65.6K | 50,437 |
| Jan 20, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 416 | $32.10 | $13.4K | 50,437 |
| Jan 15, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 19,076 | $32.66 | $623.1K | 61,804 |
| Jan 13, 2026↗ | Congleton Jon | director, officer: Chief Executive Officer | Sell | 16,236 | $32.62 | $529.6K | 646,268 |
| Jan 13, 2026↗ | Levy Adam Scott | officer: CFO and Secretary | Sell | 10,758 | $32.14 | $345.7K | 8,638 |
| Jan 13, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 8,518 | $32.56 | $277.3K | 61,804 |
| Jan 6, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 262,752 | $35.25 | $9.26M | 115,274 |
| Nov 21, 2025↗ | Slingsby Brian Taylor | Director | Sell | 1,000,000 | $43.35 | $43.35M | 7,903,840 |
| Nov 13, 2025↗ | Congleton Jon | Chief Executive Officer | Sell | 200,000 | $45.44 | $9.09M | 818,499 |
| Nov 13, 2025↗ | Gold Alexander M | Director | Sell | 34,675 | $45.45 | $1.58M | 5,000 |
| Nov 13, 2025↗ | Karydas Daphne | Director | Sell | 15,000 | $45.99 | $689.8K | 4,885 |
| Nov 13, 2025↗ | Levy Adam Scott | CFO and Secretary | Sell | 119,524 | $44.88 | $5.36M | 137,905 |
| Oct 15, 2025↗ | Congleton Jon | Chief Executive Officer | Sell | 15,100 | $42.67 | $644.3K | 832,857 |
| Oct 15, 2025↗ | Levy Adam Scott | CFO and Secretary | Sell | 10,758 | $42.01 | $452.0K | 120,257 |
| Oct 15, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 10,369 | $43.01 | $446.0K | 71,155 |
| Sep 16, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 11,367 | $36.00 | $409.3K | 83,589 |
| Sep 8, 2025↗ | AKKARAJU SRINIVAS | Buy | 588,235 | $25.50 | $15.00M | 588,235 | |
| Sep 8, 2025↗ | RA CAPITAL MANAGEMENT, L.P. | Buy | 1,176,470 | $25.50 | $30.00M | 5,456,520 | |
| Aug 14, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 11,365 | $12.93 | $147.0K | 92,891 |
| Jul 30, 2025↗ | Levy Adam Scott | CFO and Secretary | Sell | 73,678 | $14.62 | $1.08M | 193,666 |
| Jul 15, 2025↗ | Congleton Jon | Chief Executive Officer | Sell | 15,884 | $14.51 | $230.4K | 846,405 |
| Jul 15, 2025↗ | Levy Adam Scott | CFO and Secretary | Sell | 10,758 | $14.45 | $155.5K | 206,612 |
| Jul 15, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 11,366 | $14.59 | $165.9K | 97,907 |
| Jun 16, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 11,366 | $14.60 | $165.9K | 101,651 |
| May 15, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 11,366 | $15.29 | $173.8K | 106,669 |
| Apr 25, 2025↗ | Slingsby Brian Taylor | Director | Buy | 259,259 | $13.50 | $3.50M | 8,903,840 |
| Apr 15, 2025↗ | Congleton Jon | Chief Executive Officer | Sell | 15,319 | $12.19 | $186.8K | 862,289 |
| Apr 15, 2025↗ | Levy Adam Scott | CFO and Secretary | Sell | 10,757 | $12.06 | $129.7K | 215,340 |
| Apr 15, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 11,366 | $14.53 | $165.2K | 120,086 |
| Apr 3, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 55,771 | $15.76 | $879.0K | 141,901 |
| Mar 17, 2025↗ | RA CAPITAL MANAGEMENT, L.P. | Buy | 1,296,296 | $13.50 | $17.50M | 4,280,050 | |
| Mar 17, 2025↗ | Samsara BioCapital GP, LLC | Buy | 600,000 | $13.50 | $8.10M | 5,674,920 | |
| Jan 15, 2025↗ | Congleton Jon | Chief Executive Officer | Sell | 18,333 | $9.06 | $166.1K | 877,608 |
| Jan 15, 2025↗ | Levy Adam Scott | CFO and Secretary | Sell | 10,757 | $9.10 | $97.9K | 226,197 |
| Nov 12, 2024↗ | Rodman David Malcom | Chief Medical Officer | Sell | 5,026 | $15.00 | $75.4K | 140,991 |
| Nov 8, 2024↗ | Rodman David Malcom | Chief Medical Officer | Sell | 25,482 | $15.03 | $383.1K | 135,974 |
| Oct 15, 2024↗ | Congleton Jon | Chief Executive Officer | Sell | 15,271 | $13.52 | $206.4K | 895,941 |
| Oct 15, 2024↗ | Levy Adam Scott | CFO and Secretary | Sell | 10,757 | $13.57 | $146.0K | 236,854 |
| Jul 26, 2024↗ | Slingsby Brian Taylor | Director | Sell | 550,000 | $13.05 | $7.18M | 8,644,580 |
| Jul 18, 2024↗ | Rodman David Malcom | Chief Medical Officer | Sell | 525 | $15.00 | $7.9K | 102,873 |
| Jul 12, 2024↗ | Congleton Jon | Chief Executive Officer | Sell | 15,746 | $13.34 | $210.1K | 911,212 |
| Jul 12, 2024↗ | Levy Adam Scott | CFO and Secretary | Sell | 10,757 | $13.14 | $141.4K | 247,611 |
| Jun 20, 2024↗ | Congleton Jon | Chief Executive Officer | Sell | 49,313 | $12.01 | $592.0K | 958,505 |
| Jun 14, 2024↗ | Congleton Jon | Chief Executive Officer | Sell | 72,797 | $12.70 | $924.2K | 1,032,460 |
| Jun 13, 2024↗ | Levy Adam Scott | CFO and Secretary | Sell | 96,815 | $12.94 | $1.25M | 255,462 |
Showing 1–50 of 62
1 / 2
MLYS Insider Buying Activity
The following table shows recent insider purchases of Mineralys Therapeutics, Inc. (MLYS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 8, 2025↗ | AKKARAJU SRINIVAS | Buy | 588,235 | $25.50 | $15.00M | 588,235 | |
| Sep 8, 2025↗ | RA CAPITAL MANAGEMENT, L.P. | Buy | 1,176,470 | $25.50 | $30.00M | 5,456,520 | |
| Apr 25, 2025↗ | Slingsby Brian Taylor | Director | Buy | 259,259 | $13.50 | $3.50M | 8,903,840 |
| Mar 17, 2025↗ | RA CAPITAL MANAGEMENT, L.P. | Buy | 1,296,296 | $13.50 | $17.50M | 4,280,050 | |
| Mar 17, 2025↗ | Samsara BioCapital GP, LLC | Buy | 600,000 | $13.50 | $8.10M | 5,674,920 |
MLYS Insider Selling Activity
The following table shows recent insider sales of Mineralys Therapeutics, Inc. (MLYS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 417 | $25.65 | $10.7K | 76,140 |
| Mar 16, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 20,406 | $26.61 | $543.0K | 82,489 |
| Mar 10, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 2,171 | $26.84 | $58.3K | 82,489 |
| Feb 17, 2026↗ | Rodman David Malcom | Chief Medical Officer | Sell | 417 | $27.59 | $11.5K | 0 |
| Feb 13, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 16,863 | $28.05 | $473.0K | 50,958 |
| Feb 11, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 2,171 | $30.21 | $65.6K | 50,437 |
| Jan 20, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 416 | $32.10 | $13.4K | 50,437 |
| Jan 15, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 19,076 | $32.66 | $623.1K | 61,804 |
| Jan 13, 2026↗ | Congleton Jon | director, officer: Chief Executive Officer | Sell | 16,236 | $32.62 | $529.6K | 646,268 |
| Jan 13, 2026↗ | Levy Adam Scott | officer: CFO and Secretary | Sell | 10,758 | $32.14 | $345.7K | 8,638 |
| Jan 13, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 8,518 | $32.56 | $277.3K | 61,804 |
| Jan 6, 2026↗ | Rodman David Malcom | officer: Chief Medical Officer | Sell | 262,752 | $35.25 | $9.26M | 115,274 |
| Nov 21, 2025↗ | Slingsby Brian Taylor | Director | Sell | 1,000,000 | $43.35 | $43.35M | 7,903,840 |
| Nov 13, 2025↗ | Congleton Jon | Chief Executive Officer | Sell | 200,000 | $45.44 | $9.09M | 818,499 |
| Nov 13, 2025↗ | Gold Alexander M | Director | Sell | 34,675 | $45.45 | $1.58M | 5,000 |
| Nov 13, 2025↗ | Karydas Daphne | Director | Sell | 15,000 | $45.99 | $689.8K | 4,885 |
| Nov 13, 2025↗ | Levy Adam Scott | CFO and Secretary | Sell | 119,524 | $44.88 | $5.36M | 137,905 |
| Oct 15, 2025↗ | Congleton Jon | Chief Executive Officer | Sell | 15,100 | $42.67 | $644.3K | 832,857 |
| Oct 15, 2025↗ | Levy Adam Scott | CFO and Secretary | Sell | 10,758 | $42.01 | $452.0K | 120,257 |
| Oct 15, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 10,369 | $43.01 | $446.0K | 71,155 |
| Sep 16, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 11,367 | $36.00 | $409.3K | 83,589 |
| Aug 14, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 11,365 | $12.93 | $147.0K | 92,891 |
| Jul 30, 2025↗ | Levy Adam Scott | CFO and Secretary | Sell | 73,678 | $14.62 | $1.08M | 193,666 |
| Jul 15, 2025↗ | Congleton Jon | Chief Executive Officer | Sell | 15,884 | $14.51 | $230.4K | 846,405 |
| Jul 15, 2025↗ | Levy Adam Scott | CFO and Secretary | Sell | 10,758 | $14.45 | $155.5K | 206,612 |
| Jul 15, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 11,366 | $14.59 | $165.9K | 97,907 |
| Jun 16, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 11,366 | $14.60 | $165.9K | 101,651 |
| May 15, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 11,366 | $15.29 | $173.8K | 106,669 |
| Apr 15, 2025↗ | Congleton Jon | Chief Executive Officer | Sell | 15,319 | $12.19 | $186.8K | 862,289 |
| Apr 15, 2025↗ | Levy Adam Scott | CFO and Secretary | Sell | 10,757 | $12.06 | $129.7K | 215,340 |
| Apr 15, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 11,366 | $14.53 | $165.2K | 120,086 |
| Apr 3, 2025↗ | Rodman David Malcom | Chief Medical Officer | Sell | 55,771 | $15.76 | $879.0K | 141,901 |
| Jan 15, 2025↗ | Congleton Jon | Chief Executive Officer | Sell | 18,333 | $9.06 | $166.1K | 877,608 |
| Jan 15, 2025↗ | Levy Adam Scott | CFO and Secretary | Sell | 10,757 | $9.10 | $97.9K | 226,197 |
| Nov 12, 2024↗ | Rodman David Malcom | Chief Medical Officer | Sell | 5,026 | $15.00 | $75.4K | 140,991 |
| Nov 8, 2024↗ | Rodman David Malcom | Chief Medical Officer | Sell | 25,482 | $15.03 | $383.1K | 135,974 |
| Oct 15, 2024↗ | Congleton Jon | Chief Executive Officer | Sell | 15,271 | $13.52 | $206.4K | 895,941 |
| Oct 15, 2024↗ | Levy Adam Scott | CFO and Secretary | Sell | 10,757 | $13.57 | $146.0K | 236,854 |
| Jul 26, 2024↗ | Slingsby Brian Taylor | Director | Sell | 550,000 | $13.05 | $7.18M | 8,644,580 |
| Jul 18, 2024↗ | Rodman David Malcom | Chief Medical Officer | Sell | 525 | $15.00 | $7.9K | 102,873 |
| Jul 12, 2024↗ | Congleton Jon | Chief Executive Officer | Sell | 15,746 | $13.34 | $210.1K | 911,212 |
| Jul 12, 2024↗ | Levy Adam Scott | CFO and Secretary | Sell | 10,757 | $13.14 | $141.4K | 247,611 |
| Jun 20, 2024↗ | Congleton Jon | Chief Executive Officer | Sell | 49,313 | $12.01 | $592.0K | 958,505 |
| Jun 14, 2024↗ | Congleton Jon | Chief Executive Officer | Sell | 72,797 | $12.70 | $924.2K | 1,032,460 |
| Jun 13, 2024↗ | Levy Adam Scott | CFO and Secretary | Sell | 96,815 | $12.94 | $1.25M | 255,462 |
MLYS Insiders
Similar Stocks to MLYS
VRTX
Vertex Pharmaceuticals Incorporated
$452.29-2.20%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$745.34-1.66%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$317.24-0.96%
$42.07B
INSM
Insmed Incorporated
$143.85-0.06%
$30.07B
UTHR
United Therapeutics Corporation
$531.23-1.63%
$23.50B
MRNA
Moderna, Inc.
$52.27-3.15%
$20.76B
ROIV
Roivant Sciences Ltd.
$27.86-1.55%
$20.08B
RPRX
Royalty Pharma plc
$45.94-0.36%
$19.56B